Vas Narasimhan, CEO of Novartis, has been appointed to the board of directors at Anthropic, a move that gives the Long-Term Benefit Trust appointees a majority on the seven-member board. The Trust, an independent entity with no economic interest in Anthropic, ensures the company's governance aligns with its public benefit mission. Narasimhan, a medical scientist and member of the U.S. National Academy of Medicine, brings extensive experience from his leadership at Novartis, where he oversaw the development of over 35 new drugs. Anthropic co-founder Daniela Amodei highlighted Narasimhan's expertise in navigating regulated industries as a valuable asset to the company.